Hamilton Lane Advisors LLC increased its position in CytomX Therapeutics Inc (NASDAQ:CTMX) by 77.8% during the 4th quarter, HoldingsChannel reports. The firm owned 50,394 shares of the biotechnology company’s stock after acquiring an additional 22,048 shares during the quarter. Hamilton Lane Advisors LLC’s holdings in CytomX Therapeutics were worth $1,064,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in CTMX. Russell Investments Group Ltd. grew its stake in CytomX Therapeutics by 1.3% in the second quarter. Russell Investments Group Ltd. now owns 22,134 shares of the biotechnology company’s stock worth $343,000 after purchasing an additional 292 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in CytomX Therapeutics by 17.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 117,642 shares of the biotechnology company’s stock worth $1,824,000 after purchasing an additional 17,551 shares in the last quarter. Rhumbline Advisers grew its stake in CytomX Therapeutics by 48.4% in the second quarter. Rhumbline Advisers now owns 32,517 shares of the biotechnology company’s stock worth $504,000 after purchasing an additional 10,607 shares in the last quarter. Bank of New York Mellon Corp grew its stake in CytomX Therapeutics by 33.9% in the second quarter. Bank of New York Mellon Corp now owns 115,777 shares of the biotechnology company’s stock worth $1,794,000 after purchasing an additional 29,319 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in CytomX Therapeutics by 28.6% in the second quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 1,434 shares in the last quarter. 63.13% of the stock is currently owned by institutional investors.

Shares of CytomX Therapeutics Inc (CTMX) traded up $0.82 during midday trading on Wednesday, reaching $25.65. The company’s stock had a trading volume of 204,314 shares, compared to its average volume of 367,782. The company has a market cap of $966.75 and a PE ratio of -16.34. CytomX Therapeutics Inc has a 1-year low of $11.11 and a 1-year high of $25.79.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.14). CytomX Therapeutics had a negative net margin of 113.64% and a negative return on equity of 92.42%. research analysts predict that CytomX Therapeutics Inc will post -1.58 earnings per share for the current fiscal year.

Several brokerages recently issued reports on CTMX. Cowen reissued an “outperform” rating on shares of CytomX Therapeutics in a research note on Thursday, October 5th. BidaskClub raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 15th. Wedbush set a $37.00 price objective on CytomX Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, October 4th. Zacks Investment Research raised CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Monday, October 16th. Finally, Citigroup began coverage on CytomX Therapeutics in a research note on Friday, January 5th. They issued a “buy” rating and a $40.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $32.78.

In other CytomX Therapeutics news, CEO Sean A. Mccarthy sold 14,342 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $19.86, for a total transaction of $284,832.12. Following the sale, the chief executive officer now owns 18,587 shares of the company’s stock, valued at approximately $369,137.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Debanjan Ray sold 2,500 shares of the stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $20.00, for a total value of $50,000.00. Following the sale, the chief financial officer now directly owns 12,126 shares in the company, valued at approximately $242,520. The disclosure for this sale can be found here. Insiders have sold a total of 70,760 shares of company stock worth $1,533,840 in the last ninety days. Insiders own 8.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “CytomX Therapeutics Inc (CTMX) Shares Bought by Hamilton Lane Advisors LLC” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/01/17/cytomx-therapeutics-inc-ctmx-shares-bought-by-hamilton-lane-advisors-llc.html.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.